Helsinn and Mundipharma have entered an exclusive license and distribution agreement for China, Hong Kong and Macao, for Helsinn’s netupitant-palonosetron fixed dose combination (NEPA), currently in Phase III development for the treatment of chemotherapy-induced nausea and vomiting. The agreement consolidates the previously established alliance granting rights to the same combination product in Middle East and North African countries and selected South-Eastern Asian countries.   NEPA is a fixed-...